Second- and third-generation aromatase inhibitors as first-line endocrine therapy in postmenopausal metastatic breast cancer patients: a pooled analysis of the randomised trials

The purpose of this study was to estimate in all randomised trials the relative risk of overall response rate (ORR), clinical benefit (CB), time to progression (TTP), overall survival (OS), and toxicity of aromatase inhibitors (AI), compared with tamoxifen (Tam) as first-line endocrine therapy in po...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Ferretti, G, Bria, E, Giannarelli, D, Felici, A, Papaldo, P, Fabi, A, Di Cosimo, S, Ruggeri, E M, Milella, M, Ciccarese, M, Cecere, F L, Gelibter, A, Nuzzo, C, Cognetti, F, Terzoli, E, Carlini, P
Format: Artigo
Idioma:Inglês
Publicat: Nature Publishing Group 2006
Matèries:
Clinical Study
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC2361349/
https://ncbi.nlm.nih.gov/pubmed/16736002
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/sj.bjc.6603194
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars